Remove tag uk-biotech
article thumbnail

Drug-resistant epilepsy drug Ontozry backed by NICE

pharmaphorum

Epilepsy affects more than 600,000 people in the UK and for some, seizures can be life-threatening. It is estimated that around 1,000 people die in the UK every year because of the condition. “We look forward to the full technology appraisal guidance (TAG) which is due to be published in early December 2021,” he added. .

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. Oral therapy data presented at ASH.

article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

In recent years, the UK pharmaceutical industry has relied heavily on China and India as providers of active pharmaceutical ingredients. Neil Keegan is head of manufacturing at Automata, a London-based biotech company providing robotic automation solutions to the life sciences industry. Reducing capacity issues. About the author.